Author Archives: Jose Marques Lopes PhD

Ultomiris Normalizes Blood Markers, Improves Kidney Function in aHUS Patients, Phase 3 Trial Shows

Treatment with Ultomiris (ravulizumab-cwvz) normalized platelet counts, eased hemolysis  (destruction of red blood cells), and improved kidney function in a Phase 3 trial in patients with atypical hemolytic uremic syndrome (aHUS) who had not been treated with complement inhibitors. Specifically, 53.6% of patients showed complete thrombotic microangiopathy (TMA)…